New drug approval boosts market confidence: The US Food and Drug Administration (FDA) has officially approved the oral psoriasis treatment jointly developed by Protagonist Therapeutics and Johnson & Johnson. Driven by this news, Protagonist's stock price rose by about 4% in pre-market trading.

This regulatory approval marks a significant breakthrough for the two companies in the field of autoimmune disease treatment. **Broad Prospects for the Psoriasis Drug Market** Psoriasis, as a chronic immune-mediated skin disease, affects more than 125 million people worldwide, with moderate to severe cases accounting for about 20%. Traditional treatments mainly rely on injectable biologics, while the approval of oral medications will provide patients with a more convenient treatment option. According to Evaluate Pharma's forecast, the global psoriasis treatment market is expected to reach $35 billions by 2028. The newly approved oral drug, with its innovative mechanism, is expected to occupy an important position in the highly competitive market. **Collaborative Development Model Highlights Synergy** Protagonist, a biotechnology company focused on peptide drug development, has partnered with pharmaceutical giant Johnson & Johnson, demonstrating a complementary resource model within the industry. Johnson & Johnson, with its strong commercialization capabilities and global distribution network, will accelerate the market promotion of this drug. Analysts point out that this "biotech innovation + big pharma commercialization" cooperation model is particularly important against the backdrop of rising drug development costs. **Market Reaction and Future Outlook** In addition to the rise in Protagonist's stock price, Johnson & Johnson's stock also showed a moderate upward trend. Wall Street analysts generally believe that the approval of this drug will further strengthen Johnson & Johnson's leadership in the field of immune diseases. Next, the market's focus will shift to the drug's pricing strategy, insurance coverage, and sales performance after its launch. Industry insiders expect the drug to officially enter the US market in the coming months.